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RANKLInterleukin (IL)-3, a multilineage hematopoietic growth factor, is implicated in the regulation of osteo-
clastogenesis. However, the role of IL-3 in osteoclastogenesis remains controversial; whereas early stud-
ies showed that IL-3 stimulates osteoclastogenesis, recent investigations demonstrated that IL-3 inhibits
osteoclast formation. The objective of this work is to further address the role of IL-3 in osteoclastogenesis.
We found that IL-3 treatment of bone marrow cells generated a population of cells capable of differen-
tiating into osteoclasts in tissue culture dishes in response to the stimulation of the monocyte/macro-
phage-colony stimulating factor (M-CSF) and the receptor activator of nuclear factor kappa B ligand
(RANKL). The IL-3-dependent hematopoietic cells were able to further proliferate and differentiate in
response to M-CSF stimulation and the resulting cells were also capable of forming osteoclasts with
M-CSF and RANKL treatment. Interestingly, IL-3 inhibits M-CSF-/RANKL-induced differentiation of the
IL-3-dependent hematopoietic cells into osteoclasts. The ﬂow cytometry analysis indicates that while
IL-3 treatment of bone marrow cells slightly affected the percentage of osteoclast precursors in the sur-
viving populations, it considerably increased the percentage of osteoclast precursors in the populations
after subsequent M-CSF treatment. Moreover, osteoclasts derived from IL-3-dependent hematopoietic
cells were fully functional. Thus, we conclude that IL-3 plays dual roles in osteoclastogenesis by promot-
ing the development of osteoclast progenitors but inhibiting the osteoclastogenic process. These ﬁndings
provide a better understanding of the role of IL-3 in osteoclastogenesis.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Osteoclasts, the bone-resorbing cells, play an important role in
skeletal development and adult bone remodeling [1,2]. Osteoclasts
differentiate from hematopoietic cells of the monocyte/macro-
phage lineage involving several different stages [3]. Hematopoietic
stem cells (HSC) give rise to common myeloid progenitors (CMP)
with stimulation of various factors including stem cell factor
(SCF), IL-3 and interleukin 6 (IL-6). IL-3 and/or the granulocyte/
macrophage-colony stimulating factor (GM-CSF) further promote
development of CMP into granulocyte/macrophage progenitors
(GMP). CMP and GMP are collectively considered osteoclast pro-
genitors. M-CSF then promotes GMP to differentiate into cells of
the monocyte/macrophage lineage [4,5], which are osteoclast pre-
cursors. M-CSF and RANKL are two essential and sufﬁcient factors
driving osteoclast precursors to differentiate into osteoclasts [6,7].
Fig. 1. IL-3 treatment of bone marrow cells generates a population of cells capable
of forming osteoclasts. (A) A brief description of the experimental procedure. Bone
marrow cells (BMC) were cultured for 24 h (h) in tissue culture dishes. Nonadherent
cells were then moved to new tissue culture dishes and cultured with vehicle (Veh,
i.e., PBS) or IL-3 (1 ng/ml) for up to 6 days (d). At day 3 and day 6, surviving cells
were counted and quantiﬁed in panel B. Cells from the 6 days cultures were used to
perform osteoclast (OC) assays, and the results are shown in panel C. (B)
6  106 Cells were added to one 60-mm tissue culture dish and the assay was
performed in triplicate. Data are expressed as mean ± S.D. ⁄p < 0.05; ⁄⁄p < 0.01. (C)
Different numbers of surviving cells from the 6 days culture described in (A) were
seeded in 24-well tissue culture plates and cultured with 44 ng/ml M-CSF and
100 ng/ml RANKL for 5 days. The cultures were then stained for TRAP activity. The
assay was independently repeated 3 times and a representative area from each
condition is shown.
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motes the proliferation, differentiation and/or survival of early
multilineage hematopoietic progenitors [8]. In particular, this cyto-
kine plays a key role in stimulating the proliferation and survival of
myeloid precursors. By the early 1980s, it had been well estab-
lished that osteoclasts differentiate from hematopoietic cells of
the monocyte/macrophage lineage [9]. Given the role of IL-3 in
the proliferation and survival of myeloid precursors, a number of
groups investigated the potential role of IL-3 in osteoclastogenesis
in vitro in the late 1980s [10–14]. Collectively, these early investi-
gations demonstrated that IL-3 stimulates osteoclastogenesis
in vitro using either organ cultures or whole bone marrow cultures.
Intriguingly, numerous recent studies showed that IL-3 inhibits
osteoclast formation in in vitro osteoclastogenesis assays in which
osteoclast precursors were treated with the two essential osteo-
clast factors M-CSF and RANKL [15–19]. Importantly, these studies
indicate that the inhibitory regulation in the osteoclastogenesis as-
says results from the direct effect of IL-3 on osteoclast precursors.
Thus, the role of IL-3 in osteoclastogenesis remains controversial.
In this study, we seek to further address the role of IL-3 in
osteoclastogenesis. Our results demonstrate that IL-3 stimulates
the development of osteoclast progenitors from bone marrow cells,
but it inhibits differentiation of osteoclast precursors into
osteoclasts.
2. Materials and methods
2.1. Chemicals and biological reagents
Recombinant mouse IL-3 was obtained from R&D System, Inc.
(Minneapolis, MN). Mouse M-CSF was prepared as culture super-
natants from CMG14-12 cells, an M-CSF-producing cell line kindly
provided by Dr. Sunao Takeshita [20]. Recombinant GST-RANKL
was prepared in our laboratory as previously described [21]. Phy-
coerythrin (PE)-conjugated anti-mouse CD11b antibody and allo-
phycocyanin (APC)-conjugated rat IgG2a k isotype control
antibody were obtained from eBioscience (San Diego, CA). APC-
conjugated anti-mouse CD115 (c-Fms) antibody was purchased
from BioLegend (San Diego, CA). PE-conjugated rat IgG2a k isotype
control antibody was from BD Pharmingen (San Jose, CA).
2.2. Preparation and culture of mouse bone marrow cells
C57BL/6 mice were obtained from Harlan Industries (Indianap-
olis, IN). The experiments involving mice were approved by the
Institutional Animal Care and Use Committee at the University of
Alabama at Birmingham. Bone marrow cells were obtained from
long bones of young (4–6 week-old) mice and cultured in a-mini-
mal essential medium (a-MEM) containing 10% heat-inactivated
fetal bovine serum (FBS) in the presence of different factors as indi-
cated in individual experiments.
2.3. In vitro osteoclastogenesis assay
Different numbers of cells as speciﬁed in individual assays were
seeded in wells of 24-well tissue culture plates and cultured in a-
MEM supplemented with 44 ng/ml M-CSF plus RANKL 100 ng/ml
for 5 days. The osteoclastogenesis cultures were then stained for
tartrate resistant acid phosphatase (TRAP) activity with the Leuko-
cyte Acid Phosphatase kit (387-A) from Sigma–Aldrich (St. Louis,
MO).
2.4. Flow cytometry
1  106 cells were washed with cold phosphate-buffered buf-
fers (PBS) and resuspended in 200 ll blocking buffer (PBS/0.5%BSA/0.1% Azide) containing 2.4G2 antibody (5 lg/ml) for 30 min
on ice. Cells were then washed with 500 ll PBS/azide before addi-
tion of 0.5 ll PE-conjugated anti-CD11b antibody and APC-conju-
gated anti-CD115 antibody or corresponding control IgG
antibodies. The mixtures were incubated on ice for 30 min under
dim light and then washed with 1 ml cold PBS/azide twice. Cells
were ﬁxed with 400 ll cold 1% formaldehyde and analyzed using
Accuri C6 Flow Cytometor.2.5. In vitro bone resorption assay
Cells are seeded on bovine bone slices in 24-well culture
plates and cultured as indicated in individual experiments to pro-
mote osteoclastogenesis and bone resorption. Bone slices were
harvested and cells were removed with 0.25 M ammonium
hydroxide and mechanical agitation. Bone pits were analyzed by
scanning electron microscopy (SEM) using a Philips 515 scanning
microscope.2.6. Semi-quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was isolated from the cells using TRIzol reagent from
Invitrogen (Carlsbad, CA) and 1 lg of total RNA was reversed-tran-
scribed to cDNA with oligo(dT) using the ThermoScript™ RT-PCR
system (Invitrogen). Semi-quantitative RT-PCR experiments were
performed using the primers and conditions described previously
[22].
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Cell numbers are presented as mean ± S.D. Statistical signiﬁ-
cance was determined using Student t test. A p value less than
0.05 was considered signiﬁcant.3. Results
3.1. IL-3 treatment of mouse bone marrow cells generates a population
of cells capable of forming osteoclasts
Although recent studies demonstrated that IL-3 exerts inhibi-
tory effects on the osteoclastogenic process [15–19], numerous
early investigations involving organ cultures or whole bone
marrow cultures showed that IL-3 promotes osteoclastogenesisFig. 2. M-CSF further enhances the osteoclastogenic potential of IL-3-dependent cells and
brief description of the experimental procedure. Bone marrow cells (BMC) were culture
tissue culture dishes and cultured with IL-3 for 3 or 6 days (d). Then some of the surviv
assay (OC Assay 1), and remaining cells were continued with 220 ng/ml M-CSF for 4 days
IL-3 treatment. The cells were seeded in 24-well tissue culture plates (2.5  104 cells/well
M and 100 ng/ml R plus 1 ng/ml IL-3 for 5 days. (C) Quantiﬁcation of assays in B. M
magniﬁcation) was counted. Bars show averages of three replicates ± S.D. ⁄⁄p < 0.01. (D)
performed as in B. (E) Assays in D were quantiﬁed as in C. Bars show averages of three re
independently repeated 2 times and a representative area from each condition is shown[10–14]. These conﬂicting ﬁndings suggest that IL-3 may exert dual
effects on osteoclastogenesis; while IL-3 inhibits the differentiation
of osteoclast precursors into mature osteoclasts, it may also pro-
mote the differentiation, proliferation and/or survival of osteoclast
progenitors or precursors since it has been well established that IL-
3 supports the growth and development of early hematopoietic
multilineage progenitors in cell culture [8,23]. Thus, our ﬁrst
experiment aimed to address this possibility. As depicted in
Fig. 1A, we cultured whole bone marrow cells in tissue culture
dishes overnight to remove bone marrow stromal cells. Then, non-
adherent cells were moved to new tissue culture dishes, in which
the cells continued to be cultured for 3 or 6 days without IL-3 (con-
trol) or with IL-3. While no cells survived in the control culture
dishes after the 6-day culturing, the IL-3-treatment gave rise to a
signiﬁcant number of surviving cells (Fig. 1B). To determine
whether the surviving cells can form osteoclasts, they were seededIL-3 inhibits the differentiation of IL-3-dependent progenitors into osteoclasts. (A) A
d for 24 h (h) in tissue culture dishes. Nonadherent cells were then moved to new
ing cells from the 3 days and 6 days cultures were used to perform osteoclast (OC)
prior to OC assay (OC Assay 2). (B) OC Assay 1 and OC Assay 2 with cells from 3-day
) and cultured with 44 ng/ml M-CSF (M) and 100 ng/ml RANKL (R), or with 44 ng/ml
ultinucleated TRAP-positive cells (>3nuclei) per representative view area (40
OC Assay 1 and OC Assay 2 with cells from 6-day IL-3 treatment. The assays were
plicates ± S.D. ⁄⁄p < 0.01. The cultures were stained for TRAP activity. The assay was
.
Fig. 3. IL-3 promotes the development of osteoclast progenitors. (A) A brief
description of the experimental procedure. Bone marrow cells (BMC) were cultured
for 24 h (h) in tissue culture dishes. Nonadherent cells were then moved to new
tissue culture dishes and cultured with IL-3 for 0, 3 or 6 days. Then, some of the
surviving cells were used to perform ﬂow cytometric assays to determine surface
expression of CD11b and CD115 (c-Fms) (Flow a, b and c), and remaining cells were
continued with 220 ng/ml M-CSF for 4 days prior to ﬂow cytometric assays (ﬂow d,
e and f). (B) Results of ﬂow cytometric assays (a, b, c, d, e and f) as described in (A).
The assay was independently repeated 2 times and similar results were obtained.
One set of the data is shown.
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ted with M-CSF and RANKL for 5 days. As shown in Fig. 1C, M-CSF
and RANKL were able to stimulate these cells to form osteoclasts in
tissue culture dishes, indicating that IL-3 promotes the differentia-
tion, proliferation and/or survival of osteoclast progenitors or
precursors.
3.2. M-CSF further enhances the osteoclastogenic potential of IL-3
dependent hematopoietic progenitors and IL-3 inhibits the differen-
tiation of IL-3 dependent hematopoietic progenitors into osteoclasts
Next, we examined the effect of M-CSF treatment on the osteo-
clastogenic potential of IL-3 dependent hematopoietic cells. To this
end, we repeated the assay in Fig. 1A with IL-3 treatment for 3 or
6 days (Fig. 2A). At day 3, cells were treated with M-CSF and RANKL
in the absence or presence of IL-3 to assess their ability to form
osteoclasts and the potential effect of IL-3 on the osteoclastogenic
process (OC Assay 1, Fig. 2B). The remaining cells were further cul-
tured with M-CSF for 4 days (Fig. 2A) and then used to repeat the
same set of assays (OC Assay 2, Fig. 2B). These experiments were
also performed with hematopoietic cells resulting from 6-day IL-
3 treatment (Fig. 2D). While IL-3 dependent hematopoietic cells
were able to form osteoclasts (OC Assay 1, Fig. 2B/D), subsequent
M-CSF treatment of these cells gave rise to much bigger osteoclasts
(OC Assay 2, Fig. 2B/D) as well as more multinucleated TRAP-posi-
tive cells (Fig. 2C/E). Moreover, IL-3 inhibits M-CSF-/RANKL-
induced differentiation of IL-3 dependent hematopoietic cells into
osteoclasts (Fig. 2B–E). These ﬁndings indicate that (a) M-CSF can
further enhance the osteoclastogenic potential of IL-3-dependent
hematopoietic progenitors and (b) IL-3 inhibits the differentiation
of IL-3 dependent hematopoietic progenitors into osteoclasts.
3.3. IL-3 promotes the development of osteoclast progenitors
To delineate the mechanism underlying the difference in the
osteoclastogenic potential seen in Fig. 2, we next sought to deter-
mine the percentage of osteoclast precursors in the IL-3-dependent
cell population prior to and after M-CSF stimulation using two
known markers for osteoclast precursors, namely, CD11b and
CD115 (c-Fms) [24]. To this end, we prepared bone marrow cells
without IL-3 treatment or with IL-3 treatment for 3 or 6 days
(Fig. 3A). While some of these cells were used to perform ﬂow
cytometry assays to assess surface expression of CD11b and
CD115, remaining cells were further treated with M-CSF for 4 days
prior to ﬂow cytometry assays (Fig. 3A). The data indicate that IL-3
treatment of bone marrow cells slightly affected the percentage of
osteoclast precursors with 8.88%, 13.8% and 9.41% osteoclast pre-
cursors in bone marrow cells without IL-3 treatment, with 3-day
IL-3 treatment, and with or 6-day IL-3 treatment, respectively
(Fig. 3a–c). Interestingly, subsequent M-CSF treatment of these
bone marrow cells yielded increased percentages of osteoclast pre-
cursors with 38.1% osteoclast precursors in bone marrow cells
without IL-3 treatment compared to 67.0% and 69.1% osteoclast
precursors in bone marrow cells with 3-day IL-3 treatment and
with or 6-day IL-3 treatment, respectively (Fig. 3d–f). Thus, IL-3-
treated bone marrow cells had more osteoclast progenitors, indi-
cating that IL-3 promotes the development of osteoclast
progenitors.
3.4. Osteoclasts derived from IL-3-dependent hematopoietic cells are
functional
To further establish the role of IL-3 in the development of osteo-
clast progenitors, we determined whether osteoclasts generated
from IL-3-dependent hematopoietic cells have the capacity to re-
sorb bone. Bone marrow cells maintained with IL-3 for 5 or 6 dayswere seeded on bone slices in a 24-well tissue culture plate and
cultured with M-CSF alone (control) or M-CSF and RANKL for
9 days. Then bone slices were processed for SEM analysis
(Fig. 4A). The data show that osteoclasts generated from IL-3-
dependent hematopoietic progenitors are capable of resorbing
bones. In parallel, some bone marrow cells maintained with IL-3
for 5 or 6 days were further cultured with M-CSF for 4 days prior
to being used for bone resorption assays (Fig. 4B). We found that
osteoclasts derived from IL-3-dependent hematopoietic progeni-
tors with further M-CSF treatment are also functional.
We next investigated osteoclast gene expression in osteoclasts
generated from IL-3-dependent hematopoietic cells. Bone marrow
cells cultured with IL-3 for 6 days were seeded in tissue culture
dishes with M-CSF alone (control) or M-CSF and RANKL for 5 days.
Moreover, bone marrow cells treated with IL-3 for 6 days were
Fig. 4. IL-3-dependent cells can form functional osteoclasts and a model for the role of IL-3 in osteoclast biology. (A) Bone marrow cells (BMC) were cultured for 24 h (h) in
tissue culture dishes. Nonadherent cells were then moved to new tissue culture dishes and cultured with IL-3 for 5 or 6 days (d). 1  105 of surviving cells were seeded on
bone slices in 24-well tissue culture plates and cultured with 44 ng/ml M-CSF alone or with 44 ng/ml M-CSF and 100 ng/ml RANKL for 9 days to perform bone resorption
assays. (B) BMC were cultured for 24 h in tissue culture dishes. Nonadherent cells were then moved to new tissue culture dishes and cultured with IL-3 for 5 or 6 days,
followed by M-CSF treatment (44 ng/ml) for 4 days. Then 5  104 of cells were seeded on bone slices in 24-well tissue culture plates and cultured with 44 ng/ml M-CSF alone
or with 44 ng/ml M-CSF and 100 ng/ml RANKL for 9 days to perform bone resorption assays. These assays were independently repeated 2 times and a representative area is
shown. (C) BMC were cultured for 24 h in tissue culture dishes. Nonadherent cells were then moved to new tissue culture dishes and cultured with IL-3 for 6 days. Then, some
of the surviving cells were cultured with 44 ng/ml M-CSF alone (control) or with 44 ng/ml M-CSF and 100 ng/ml RANKL for 5 days to form osteoclasts. The remaining cells
were continued with M-CSF (44 ng/ml) for 5 days, followed by treatment with M-CSF alone or M-CSF (44 ng/ml) and RANKL (100 ng/ml) for 5 days. The expression of
representative osteoclasts genes (MMP9, Ctsk, TRAP and Car2) was assessed by semi-quantitative RT-PCR. GAPDH was used as control. The assay was independently repeated
2 times. (D) A model for the role of IL-3 in osteoclastogenesis in the context of normal bone remodeling.
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in tissue culture dishes with M-CSF alone (control) or M-CSF and
RANKL for 5 days. The expression of four osteoclast genes (Ctsk,
cathepsin K; MMP9, matrix metalloproteinase 9; Car2, carbonic
anhydrase 2; and TRAP, tartrate acid resistant phosphatase) was
assessed by semi-quantitative RT-PCR using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as control. As shown in
Fig. 4C, all these osteoclast genes are expressed in IL-3-dependent
hematopoietic progenitors treated with M-CSF and RANKL but not
in those treated with M-CSF alone. The data demonstrate that
osteoclasts generated from IL-3-dependent hematopoietic cells ex-
press osteoclast genes, thus further indicating that osteoclasts de-
rived from IL-3-dependent hematopoietic progenitors with further
M-CSF treatment are functional.4. Discussion
In this work, we have carried out various assays to further ad-
dress the role of IL-3 in osteoclastogenesis. Our key ﬁndings are
(a) IL-3 treatment of bone marrow cells can generate a population
of cells capable of forming osteoclasts in tissue culture dishes in re-
sponse to subsequent M-CSF and RANKL stimulation (Fig. 1); (b)
M-CSF can further enhance the osteoclastogenic potential of IL-3-dependent hematopoietic progenitors (Fig. 2); (c) IL-3 inhibits
the differentiation of IL-3-dependent hematopoietic progenitors
into osteoclasts (Fig. 2); and (d) IL-3 promotes the development
of osteoclast progenitors (Fig. 3). Moreover, given the controversy
on the role of IL-3 in osteoclastogenesis, we extended our study
to conﬁrm that osteoclasts derived from IL-3-dependent hemato-
poietic cells are functional (Fig. 4A–C).
Our ﬁnding is consistent with the conclusions from early stud-
ies that IL-3 stimulates osteoclastogenesis in organ or whole bone
marrow cultures [10–14], which contained different cell types
including bone marrow stromal cells. We used bone marrow cells
depleted of bone marrow stromal cells. Thus, our study provides
evidence that IL-3 promotes the development of osteoclast progen-
itors by directly targeting hematopoietic progenitors. Also, we have
replicated recent observations that IL-3 inhibits the osteoclasto-
genic process [15–19]. The opposite effects of IL-3 on different
stages of osteoclastogenesis have led to an important question –
what is the net effect of IL-3 on osteoclastogenesis and bone
remodeling? We feel that this question should be answered in
the context of the newly proposed model for bone remodeling.
Based on numerous recent studies [25–27], it is proposed that
osteoclastogenesis occurs within a closed space termed ‘‘bone
remodeling compartment (BRC)’’, which is very vascular and char-
acterized by the presence of a canopy formed by bone lining cells
550 H. Hong et al. / Biochemical and Biophysical Research Communications 440 (2013) 545–550[2] (Fig. 4D). Bone remodeling can be divided into four major
stages [2]. Stage 1: initiation of bone remodeling by recruitment
of osteoclast precursors into the BRC; Stage 2: bone resorption
phase characterized by predominant osteoclast formation and
function (bone resorption) with concurrent recruitment of mesen-
chymal stem cells (MSC)/osteoprogenitors into the BRC; Stage 3:
bone formation stage which involve primarily osteoblast differen-
tiation and function (osteoid synthesis); and lastly Stage 4: miner-
alization of osteoid and termination of bone remodeling.
This newly proposed model highlights the notion that develop-
ment of osteoclast progenitors/precursors is spatially separated
from the formation of mature osteoclasts. Speciﬁcally, the develop-
ment of osteoclast progenitors/precursors occurs within the bone
marrow space (Fig. 4D). HSC give rise to CMP with stimulation of
various factors such as IL-3, stem cell factor (SCF) and IL-6. IL-3
and/or GM-CSF further promote development of CMP into GMP.
CMP and GMP are considered osteoclast progenitors (Fig. 4D). With
stimulation by M-CSF, GMP in turn differentiate into cells of the
monocyte/macrophage lineage [4,5], which are considered osteo-
clast precursors. In contrast, osteoclast differentiation occurs with-
in the BRC in which M-CSF and RANKL produced by osteoblasts
and/or osteocytes stimulate osteoclast differentiation (Fig. 4D). Gi-
ven that activated T-cells, but not osteoblasts or osteocytes, are
majors sources of IL-3, IL-3 is unlikely to be present in the BRC
to have a signiﬁcant impact on osteoclastogenesis in normal bone
remodeling. However, it is possible that IL-3 may play a role in reg-
ulating osteoclastogenesis in pathological conditions under which
the integrity of the BRC is compromised and/or IL-3-producing
cells such as activated T-cells mistakenly enter the BRC.
In conclusion, this work reveals that IL-3 exerts dual effects on
osteoclastogenesis in that it promotes the development of osteo-
clast progenitors but inhibits the osteoclastogenic process. Signiﬁ-
cantly, these ﬁndings not only provide a better understanding of
the role of IL-3 in osteoclastogenesis but may also facilitate future
studies to delineate the role of IL-3 in the pathogenesis of bone
diseases.
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